Meena Sivasankaran

Meena Sivasankaran

Auto-generated profile, based on publicly available information

Meena Sivasankaran

Department of Pediatric Hemato-Oncology and BMT, Kanchi Kamakoti CHILDS Trust Hospital, Chennai 600034, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
RURamya Uppuluri
Ramya Uppuluri
MSMeena Sivasankaran
Meena Sivasankaran
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
KRKesavan Melarcode Ramanan
Kesavan Melarcode Ramanan
RRRevathi Raj
Revathi Raj

14 February 2020 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
DNDivya Nandhakumar
Divya Nandhakumar
ALAjeitha Loganathan
Ajeitha Loganathan
MSMeena Sivasankaran
Meena Sivasankaran
SSSomu Sivabalan
Somu Sivabalan
DMDeenadayalan Munirathnam
Deenadayalan Munirathnam

20 August 2018 in Indian Pediatrics
Verified
Journal Article
Closed access
PDF file
RURamya Uppuluri
Ramya Uppuluri
DJDhaarani Jayaraman
Dhaarani Jayaraman
MSMeena Sivasankaran
Meena Sivasankaran
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
RRRevathi Raj
Revathi Raj

2 November 2021 in Fetal and Pediatric Pathology
Verified
Journal Article
Closed access
Mukul vijMukul vij
Mukul vij
MSMeena Sivasankaran
Meena Sivasankaran
DJDhaarani Jayaraman
Dhaarani Jayaraman
SSSrinivas Sankaranarayanan
Srinivas Sankaranarayanan
VKVimal Kumar
Vimal Kumar
JSJulius Scott
Julius Scott
Background: Primary immunodeficiency (PID) having defects related to lymphocyte cytotoxic pathway or T-cell dysfunction are well known for developing opportunistic infections and Epstein-Barr virus (EBV)-associated diseases. CARMIL2 deficiency is a recently described combined immunodeficiency (CID) disorder characterized by defective CD28-mediated T cell co-stimulation, altered cytoskeletal dynamics, susceptibility to various infections and Epstein Barr Virus smooth muscle tumor (EBV-SMT). Case report: We report a homozygous CARMIL2 pathogenic variant presenting with recurrent infections and EBV associated smooth muscle tumor (SMT) in a child. Conclusion: The present study reports that EBV SMT may occur in a child with CARMIL2 deficiency.

29 December 2018 in Indian Pediatrics
Verified
Journal Article
Closed access
PDF file
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
VMV Sr. Mythili
V Sr. Mythili
MVM Sr. Venkatadesikalu
M Sr. Venkatadesikalu
MSMeena Sivasankaran
Meena Sivasankaran
RRRevathi Raj
Revathi Raj

31 May 2019 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
RURamya Uppuluri
Ramya Uppuluri
SPShivani Patel
Shivani Patel
MSMeena Sivashankaran
Meena Sivashankaran
NRNikila Ravichandran
Nikila Ravichandran
RRRevathi Raj
Revathi Raj